logo
Plus   Neg
Share
Email

Baidu App Traffic Up 25% In Sept.; Q3 Adj. Revenues Up 3%

Baidu, Inc. (BIDU) said Baidu App traffic continues to grow robustly with average daily active users or DAUs reaching 189 million, up 25 percent year over year, in September and Baidu's in-app search continues to gain market share. Baidu Smart Mini Program's monthly active users or MAUs, reached 290 million, up 157 percent year over year. iQIYI subscribers reached 105.8 million, up 31 percent year over year, in September 2019.

Third-quarter non-GAAP earnings per ADS was RMB 13 or $1.76. Non-GAAP net income attributable to Baidu Core was RMB 6.3 billion or $883 million, for the quarter. On average, 16 analysts polled by Thomson Reuters expected the company to report profit per share of $1.11, for the quarter. Analysts' estimates typically exclude special items.

For the third-quarter, total revenues were RMB 28.1 billion or $3.93 billion, flat from last year and up 3 percent year over year, excluding the impact of announced divestures. Online marketing revenues were RMB 20.4 billion or $2.86 billion, decreasing 9 percent year over year. Revenue from Baidu Core reached RMB 21.0 billion or $2.94 billion, down 3 percent year over year, or up 2 percent year over year, excluding the impact of announced divestures. Analysts expected revenue of $3.88 billion, for the quarter.

For the fourth quarter of 2019, Baidu expects revenues to be between RMB 27.1 billion ($3.78 billion) and RMB 28.7 billion ($4.02 billion), between a decline of 1 percent to 6 percent increase year over year, which assumes that Baidu Core revenue will grow between flat to 6 percent year over year. Analysts expect the company to report revenue of $3.88 billion.

Shares of Baidu, Inc. were up nearly 5% after hours.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
The European Commission said Friday that it has signed a deal with Sanofi and GlaxoSmithKline to secure up to 300 million doses of their potential COVID-19 vaccine. Acella Pharmaceuticals recalled certain lots of hypothyroidism medication NP Thyroid in the form of tablets due to super potency, the U.S. Food and Drug Administration said in a statement. The company is recalling one lot of 15mg and one lot of 120mg of NP Thyroid that are packaged in 100 count bottles in strengths of 15 mg, and 120 mg, with expiration dates between October 2020 and November 2020. Walmart announced its decision to raise wages for around 165,000 hourly associates across all its U.S. stores starting October, and introduce a team-based operating model in Supercenters. In a tweet, the retail giant said, "Today we're introducing new leadership roles and cross-training opportunities, giving our associates more ways to grow their careers."
Follow RTT